Using AI to Speed up Vaccine Development Against Disease X
· CEPI to provide up to $4.98 USD million to Houston Methodist Research Institute-led consortium to use artificial intelligence for the design of vaccines to fight diseases with pandemic potential.
· The project will support a consortium led by HMRI to design potential antigenic targets for up to 10 priority virus families with epidemic or pandemic potential. Laboratory-based tests will then be used to verify antigen designs for possible further development.
· Consortium will include The University of Texas, Austin, The University of Texas Medical Branch, J Craig Venter Research Institute, La Jolla Institute, and Argonne National Laboratory (University of Chicago).
18 July 2023. OSLO, Norway: CEPI, the Coalition for Epidemic Preparedness Innovations, and the Houston Methodist Research Institute (HMRI) have today announced a partnership to combine cutting-edge artificial intelligence (AI) technology with established laboratory techniques to speed up the development of future vaccines against novel viral threats (also known as Disease X). HMRI will lead a consortium including experts from Argonne National Laboratory (University of Chicago), J Craig Venter Research Institute, La Jolla Institute, The University of Texas Medical Branch, and The University of Texas, Austin.
CEPI will provide up to US$4.98 million to HMRI to advance the application of AI to analyze the structures of viruses from priority viral families from which the next Disease X is likely to emerge. These AI approaches will be used to identify target pieces of protein in the virus that stimulate the immune system, known as epitopes. The HMRI-led consortium will initially focus its efforts on paramyxoviruses and arenaviruses, viral families which include the likes of the Nipah virus and Lassa virus, respectively.
AI experts from the HMRI, University of Texas-Austin, La Jolla Institute, and Argonne National Laboratory (University of Chicago) will use machine-learning approaches to optimize the design of potential epitopes. The University of Texas Medical Branch will then validate the immunogenicity of these potential vaccine candidates using established preclinical models.
Should a new pathogen emerge in the future, vaccine developers could quickly respond by selecting AI-identified epitopes that would have already been validated in preclinical tests, thereby enabling vaccine candidates to be moved quickly into clinical testing.
Expanding the use of AI for pandemic preparedness
In June 2023, CEPI announced a partnership with the University of Leipzig to use the Rosetta Macromolecular Modelling platform to generate state-of-the-art immunogen designs and speed up the development of future vaccines against novel viral threats. In November 2022, CEPI also partnered with the University of California, Davis, to support the application of AI to expand their “SpillOver” platform to inform prioritization of viral families with epidemic or pandemic risk.
Vaccine Library key to pandemic preparedness
Preparation of pathogen targets and vaccines through pre-clinical and clinical testing before an outbreak of a novel pathogen will streamline the development of future vaccine candidates against Disease X, potentially within 100 days of identification. This effort to compress pandemic vaccine development down to just 100 days is known as the 100 Days Mission and has been embraced by the G7 and G20.
Achieving the 100 Days Mission would give the world a fighting shot to stop the next pandemic-causing Disease X in its tracks. CEPI has a $3.5 billion plan that, over the next 5 years, will kickstart and coordinate the work necessary to achieve this mission.
A critical enabler of the 100 Days Mission is the establishment of a global ‘Vaccine Library’: a globally accessible store of scientific knowledge, data, and prototype rapid-response vaccine candidates against selected viruses from the 25 viral families known to infect humans. Components in the Vaccine Library can be swiftly utilized if a novel pathogen with pandemic potential emerges, significantly accelerating the vaccine development process
CEPI’s aim is to store AI-generated, lab-tested and verified antigen designs developed by the HMRI consortium in the Vaccine Library so they can be quickly used to develop vaccine candidates in the event of an outbreak of a novel pathogenic threat. In this scenario, these antigen designs could be taken “off the shelf” once the gene sequences of the virus causing the outbreak are known, which could then be inserted into an appropriate rapid-response vaccine platform to start the production of vaccines for clinical testing.
Beating the next Disease X
An outbreak of a future Disease X is inevitable. Forces such as globalization, urbanization, and climate change are increasing the likelihood and frequency of such outbreaks, but that inevitability does not mean the world is destined to relive the devastating impacts of COVID-19. The scientific advances forged in response to COVID-19 have equipped the world with the tools and concepts that would enable us to interrupt outbreaks in the future before they spiral out of control.
In November 2022, CEPI published a landmark report entitled “What Will It Take” that outlined the paradigm shift needed to speed up vaccine development even more, highlighting the crucial scientific and technological innovations (including the creation of a vaccine library) that will enable the world to develop new vaccines against future pandemic threats in just 100 days.
Enabling equitable access
Non-exclusive access to the components of the Vaccine Library—including virtual antigen designs—will be available to CEPI partners and other developers who agree to enable equitable access to vaccines and other countermeasures against pathogens with epidemic or pandemic potential derived from the Library, in line with CEPI’s equitable access policy.
Dr. Richard Hatchett, CEO of CEPI, said: “Stopping the next pandemic threat will require rapid development—within 100 days—of safe and effective vaccines against emerging infectious pathogens. A crucial enabler of this 100 Days Mission will be the establishment of a Global Vaccine Library.
“Building the Vaccine Library is a huge task that cannot be achieved by any one country or organization working alone. It will require coordinated investments in countermeasure development and, in outbreak situations, rapid data sharing.
“For its part, CEPI is making key investments to help the world solve many of the challenges of vaccine design in advance of an outbreak of a virus with pandemic potential. Advances in AI technology are making this possible by revolutionizing how we identify potential vaccine targets, laying the foundations for a library of AI-generated antigen designs ready to use against future pandemic threats.”
H. Dirk Sostman, M.D., President of the Houston Methodist Academic Institute, said: “We are delighted to have Houston Methodist Academic Institute be a part of this program, serving our community and the world. Leading this consortium is an amazing undertaking and a testament to the work that Dr. Jimmy Gollihar, his team in pathology and genomic medicine, and many others in our academic institute are doing to help defeat the next pandemic”.
CEPI is an innovative partnership between public, private, philanthropic, and civil organizations, launched at Davos in 2017, to develop vaccines against future epidemics. Prior to COVID-19, CEPI’s work focused on developing vaccines against the Ebola Virus Disease, Lassa virus, Middle East Respiratory Syndrome coronavirus, Nipah virus, Rift Valley Fever virus and Chikungunya virus. It has over 20 vaccine candidates against these pathogens in development. CEPI has also invested in new platform technologies for rapid vaccine development against unknown pathogens (Disease X).
During the COVID-19 pandemic, CEPI initiated multiple programs to develop vaccines against SARS-CoV-2 and its variants with a focus on speed, scale and access. These programs leverage the rapid response platforms developed by CEPI’s partners prior to the emergence of COVID-19, as well as new collaborations. The aim is to advance the clinical development of a diverse portfolio of safe and effective COVID-19 candidates and to enable fair allocation of these vaccines worldwide through COVAX.
CEPI’s 5-year plan lays out a $3.5 billion roadmap to compress vaccine development timelines to 100 days, develop a broadly protective vaccine against COVID-19 and other betacoronaviruses, and create a “library” of vaccine candidates for use against known and unknown pathogens. The plan is available at https://endpandemics.cepi.net.
Follow our news page for the latest updates. Follow us via @CEPIvaccines, @DrRHatchett, and on LinkedIn.
To read more about how the world can work together to #endpandemics, check out DISEASE X – The 100 Days Mission to End Pandemics, by CEPI’s Chief Scientific Writer Kate Kelland, available here at Bookshop.org. All author proceeds go to the World Health Organization Foundation’s COVID-19 Response.
About Houston Methodist
Houston Methodist is one of the nation’s leading health systems and academic medical centers. The health system consists of eight hospitals: Houston Methodist Hospital, its flagship academic hospital in the Texas Medical Center; six community hospitals; and one long-term acute care hospital throughout the Greater Houston area. Houston Methodist also includes a research institute; a comprehensive residency program; a physician organization; international patient services; freestanding comprehensive care, emergency care, and imaging centers; and outpatient facilities. Houston Methodist employs approximately 30,000 people and has had more than 1.9 million outpatient visits and more than 138,000 admissions in 2022.
U.S. News & World Report has named Houston Methodist Hospital the Best Hospital in Texas for 11 years in a row. Houston Methodist is the No. 1 hospital in Texas and No. 15 in the nation. For more information about Houston Methodist, visit houstonmethodist.org. Follow us on Twitter, Facebook and On Health.
Phone: +44 7387 055214